BiomX Inc. (NYSEMKT:PHGE – Get Free Report) shares were down 2.3% during trading on Tuesday . The company traded as low as $0.93 and last traded at $0.94. Approximately 34,736 shares traded hands during trading, a decline of 49% from the average daily volume of 68,601 shares. The stock had previously closed at $0.96.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of BiomX in a research report on Friday, August 16th.
Check Out Our Latest Stock Report on PHGE
BiomX Stock Down 2.3 %
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC acquired a new stake in shares of BiomX Inc. (NYSEMKT:PHGE – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned approximately 19.59% of BiomX as of its most recent filing with the SEC. 40.57% of the stock is currently owned by hedge funds and other institutional investors.
About BiomX
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Read More
- Five stocks we like better than BiomX
- How to Invest in Biotech Stocks
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Best Fintech Stocks for a Portfolio Boost
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.